THE Therapeutic Goods Administration (TGA) has given Bristol-Myers Squibb the nod to market Opdivo (nivolumab) for its eleventh indication in Australia, as monotherapy for hepatocellular carcinoma.
This is the first immuno-oncology therapy approved in Australia for this condition, but is not yet funded on the PBS.
Associate Professor Simone Strasser, Senior Staff Specialist at the AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, said the introduction of the new option for immuno-oncology therapy was welcome news for liver cancer patients and healthcare professionals.
The above article was sent to subscribers in Pharmacy Daily's issue from 25 Sep 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 25 Sep 18
